1 | double-blind | 22,638 |
2 | double-blinded | 2,117 |
3 | single-blind | 1,832 |
4 | single-blinded | 735 |
5 | double-masked | 640 |
6 | double-dummy | 460 |
7 | two-period | 249 |
8 | non-blinded | 193 |
9 | 2-period | 154 |
10 | nonblinded | 135 |
11 | three-period | 109 |
12 | 2×2 | 97 |
13 | split-face | 91 |
14 | two-treatment | 86 |
15 | single-masked | 80 |
16 | triple-blind | 78 |
17 | 3-period | 67 |
18 | four-period | 64 |
19 | two-sequence | 64 |
20 | two-by-two | 57 |
21 | four-way | 46 |
22 | investigator-masked | 46 |
23 | patient-blinded | 41 |
24 | 2-sequence | 40 |
25 | 4-way | 38 |
26 | rater-blinded | 38 |
27 | three-treatment | 36 |
28 | 2-by-2 | 33 |
29 | randomized-sequence | 32 |
30 | 2-center | 31 |
31 | 4-period | 30 |
32 | 2-treatment | 26 |
33 | cary | 25 |
34 | triple-blinded | 24 |
35 | doubleblind | 22 |
36 | random-order | 22 |
37 | monrovia | 21 |
38 | examiner-blinded | 19 |
39 | five-way | 17 |
40 | bloomington | 15 |
41 | double-placebo | 15 |
42 | participant-blinded | 15 |
43 | 3-treatment | 14 |
44 | triple-masked | 14 |
45 | 5-way | 12 |
46 | burlington | 12 |
47 | semi-randomized | 12 |
48 | 5-period | 11 |
49 | four-treatment | 10 |
50 | raritan | 10 |
51 | three-sequence | 10 |
52 | 2×3 | 9 |
53 | nonmasked | 9 |
54 | subject-blinded | 9 |
55 | allocation-concealed | 8 |
56 | doubled-blind | 8 |
57 | five-period | 8 |
58 | hirsutine | 8 |
59 | simple-blind | 8 |
60 | 4-treatment | 7 |
61 | flexible-dosing | 7 |
62 | gram-stain-negative | 7 |
63 | kindergarten-based | 7 |
64 | patient-blind | 7 |
65 | single-sequence | 7 |
66 | subject-blind | 7 |
67 | 5-center | 6 |
68 | 5-treatment | 6 |
69 | double-bind | 6 |
70 | oxyfluorfen | 6 |
71 | sequence-randomized | 6 |
72 | single-period | 6 |
73 | split-body | 6 |
74 | 2×2×2 | 5 |
75 | 3-sequence | 5 |
76 | 6-sequence | 5 |
77 | anorexia/nausea | 5 |
78 | evaluator-masked | 5 |
79 | guideline-informed | 5 |
80 | linarin | 5 |
81 | pectolinarigenin | 5 |
82 | subject-masked | 5 |
83 | tarrytown | 5 |
84 | 2×4 | 4 |
85 | 6-way | 4 |
86 | balanced-order | 4 |
87 | beta-bhc | 4 |
88 | fast-disintegrating | 4 |
89 | gas-cooled | 4 |
90 | hdac9 | 4 |
91 | histology-independent | 4 |
92 | konstanz | 4 |
93 | myosuppressin | 4 |
94 | necrobiosis | 4 |
95 | niederman | 4 |
96 | partial-factorial | 4 |
97 | pbo-controlled | 4 |
98 | pro-coagulatory | 4 |
99 | rs17366568 | 4 |
100 | two-panel | 4 |
101 | 1-group | 3 |
102 | 14-center | 3 |
103 | 23-bed | 3 |
104 | 6.25- | 3 |
105 | aclc | 3 |
106 | b.c. | 3 |
107 | bicenter | 3 |
108 | cyp2a | 3 |
109 | dedas | 3 |
110 | demographic- | 3 |
111 | esl-bid | 3 |
112 | historical-controlled | 3 |
113 | mazf | 3 |
114 | nonexplicit | 3 |
115 | nonsponsored | 3 |
116 | one-sequence | 3 |
117 | partially-blind | 3 |
118 | periinfarct | 3 |
119 | pink-pigmented | 3 |
120 | placebo-and | 3 |
121 | randomized-order | 3 |
122 | singleblind | 3 |
123 | six-contact | 3 |
124 | three-station | 3 |
125 | titration-based | 3 |
126 | yellow-pigmented | 3 |
127 | 0.10g | 2 |
128 | 16-months | 2 |
129 | 2-condition | 2 |
130 | 28-component | 2 |
131 | 2x2x2 | 2 |
132 | 40-wk | 2 |
133 | 5-sequence | 2 |
134 | 5-stage | 2 |
135 | beefy | 2 |
136 | bi-lobectomy | 2 |
137 | blinded-adjudication | 2 |
138 | chondroblasts | 2 |
139 | corkscrew | 2 |
140 | coumarines | 2 |
141 | counter-intuitively | 2 |
142 | craftsmen | 2 |
143 | ct3a | 2 |
144 | dimensionalities | 2 |
145 | dosage-ranging | 2 |
146 | dose-blinded | 2 |
147 | duodenoileostomy | 2 |
148 | easy-to-learn | 2 |
149 | expectancy-enhanced | 2 |
150 | family-member | 2 |
151 | four-phased | 2 |
152 | ga2 | 2 |
153 | high-standard | 2 |
154 | manual-electroacupuncture | 2 |
155 | mpac* | 2 |
156 | multi-crossover | 2 |
157 | nine-period | 2 |
158 | nonbiphenyl | 2 |
159 | novobiocin-based | 2 |
160 | parallel-grouped | 2 |
161 | poorly-designed | 2 |
162 | pseudosac | 2 |
163 | randomized/controlled | 2 |
164 | respirologist | 2 |
165 | response-conditional | 2 |
166 | safflower-oil | 2 |
167 | self-delimiting | 2 |
168 | sequence-crossover | 2 |
169 | seven-way | 2 |
170 | six-centre | 2 |
171 | six-period | 2 |
172 | six-site | 2 |
173 | split-wound | 2 |
174 | stepped-wedged | 2 |
175 | three-by-two | 2 |
176 | triglycerols | 2 |
177 | '2x2 | 1 |
178 | 10-sequence | 1 |
179 | 2-treatment-period | 1 |
180 | 2² | 1 |
181 | 4-intervention | 1 |
182 | 4x4 | 1 |
183 | 4×3 | 1 |
184 | 5-night | 1 |
185 | 6-period | 1 |
186 | 6-week-randomized | 1 |
187 | 7-way | 1 |
188 | 92-d | 1 |
189 | europa-trial | 1 |
190 | four-branch | 1 |
191 | four-brush | 1 |
192 | four-groups | 1 |
193 | four-variable-three-level | 1 |
194 | fully-within-groups | 1 |
195 | guilt-free | 1 |
196 | holter-based | 1 |
197 | naugle | 1 |
198 | nine-participant | 1 |
199 | one-side-blinded | 1 |
200 | orbital-specific | 1 |
201 | phytosterol-free | 1 |
202 | radial-to-fa | 1 |
203 | random-ordered | 1 |
204 | random-sequencing | 1 |
205 | randomized-group | 1 |
206 | single-dummy | 1 |
207 | three-level-three-factor | 1 |
208 | three-period- | 1 |
209 | triple-period | 1 |
210 | two-by-three | 1 |
211 | two-latin-square | 1 |
212 | ≤20-week | 1 |
1 | '2x2 | 1 |
2 | 0.10g | 2 |
3 | 1-group | 3 |
4 | 10-sequence | 1 |
5 | 14-center | 3 |
6 | 16-months | 2 |
7 | 2-by-2 | 33 |
8 | 2-center | 31 |
9 | 2-condition | 2 |
10 | 2-period | 154 |
11 | 2-sequence | 40 |
12 | 2-treatment | 26 |
13 | 2-treatment-period | 1 |
14 | 23-bed | 3 |
15 | 28-component | 2 |
16 | 2x2x2 | 2 |
17 | 2² | 1 |
18 | 2×2 | 97 |
19 | 2×2×2 | 5 |
20 | 2×3 | 9 |
21 | 2×4 | 4 |
22 | 3-period | 67 |
23 | 3-sequence | 5 |
24 | 3-treatment | 14 |
25 | 4-intervention | 1 |
26 | 4-period | 30 |
27 | 4-treatment | 7 |
28 | 4-way | 38 |
29 | 40-wk | 2 |
30 | 4x4 | 1 |
31 | 4×3 | 1 |
32 | 5-center | 6 |
33 | 5-night | 1 |
34 | 5-period | 11 |
35 | 5-sequence | 2 |
36 | 5-stage | 2 |
37 | 5-treatment | 6 |
38 | 5-way | 12 |
39 | 6-period | 1 |
40 | 6-sequence | 5 |
41 | 6-way | 4 |
42 | 6-week-randomized | 1 |
43 | 6.25- | 3 |
44 | 7-way | 1 |
45 | 92-d | 1 |
46 | aclc | 3 |
47 | allocation-concealed | 8 |
48 | anorexia/nausea | 5 |
49 | b.c. | 3 |
50 | balanced-order | 4 |
51 | beefy | 2 |
52 | beta-bhc | 4 |
53 | bi-lobectomy | 2 |
54 | bicenter | 3 |
55 | blinded-adjudication | 2 |
56 | bloomington | 15 |
57 | burlington | 12 |
58 | cary | 25 |
59 | chondroblasts | 2 |
60 | corkscrew | 2 |
61 | coumarines | 2 |
62 | counter-intuitively | 2 |
63 | craftsmen | 2 |
64 | ct3a | 2 |
65 | cyp2a | 3 |
66 | dedas | 3 |
67 | demographic- | 3 |
68 | dimensionalities | 2 |
69 | dosage-ranging | 2 |
70 | dose-blinded | 2 |
71 | double-bind | 6 |
72 | double-blind | 22,638 |
73 | double-blinded | 2,117 |
74 | double-dummy | 460 |
75 | double-masked | 640 |
76 | double-placebo | 15 |
77 | doubleblind | 22 |
78 | doubled-blind | 8 |
79 | duodenoileostomy | 2 |
80 | easy-to-learn | 2 |
81 | esl-bid | 3 |
82 | europa-trial | 1 |
83 | evaluator-masked | 5 |
84 | examiner-blinded | 19 |
85 | expectancy-enhanced | 2 |
86 | family-member | 2 |
87 | fast-disintegrating | 4 |
88 | five-period | 8 |
89 | five-way | 17 |
90 | flexible-dosing | 7 |
91 | four-branch | 1 |
92 | four-brush | 1 |
93 | four-groups | 1 |
94 | four-period | 64 |
95 | four-phased | 2 |
96 | four-treatment | 10 |
97 | four-variable-three-level | 1 |
98 | four-way | 46 |
99 | fully-within-groups | 1 |
100 | ga2 | 2 |
101 | gas-cooled | 4 |
102 | gram-stain-negative | 7 |
103 | guideline-informed | 5 |
104 | guilt-free | 1 |
105 | hdac9 | 4 |
106 | high-standard | 2 |
107 | hirsutine | 8 |
108 | histology-independent | 4 |
109 | historical-controlled | 3 |
110 | holter-based | 1 |
111 | investigator-masked | 46 |
112 | kindergarten-based | 7 |
113 | konstanz | 4 |
114 | linarin | 5 |
115 | manual-electroacupuncture | 2 |
116 | mazf | 3 |
117 | monrovia | 21 |
118 | mpac* | 2 |
119 | multi-crossover | 2 |
120 | myosuppressin | 4 |
121 | naugle | 1 |
122 | necrobiosis | 4 |
123 | niederman | 4 |
124 | nine-participant | 1 |
125 | nine-period | 2 |
126 | non-blinded | 193 |
127 | nonbiphenyl | 2 |
128 | nonblinded | 135 |
129 | nonexplicit | 3 |
130 | nonmasked | 9 |
131 | nonsponsored | 3 |
132 | novobiocin-based | 2 |
133 | one-sequence | 3 |
134 | one-side-blinded | 1 |
135 | orbital-specific | 1 |
136 | oxyfluorfen | 6 |
137 | parallel-grouped | 2 |
138 | partial-factorial | 4 |
139 | partially-blind | 3 |
140 | participant-blinded | 15 |
141 | patient-blind | 7 |
142 | patient-blinded | 41 |
143 | pbo-controlled | 4 |
144 | pectolinarigenin | 5 |
145 | periinfarct | 3 |
146 | phytosterol-free | 1 |
147 | pink-pigmented | 3 |
148 | placebo-and | 3 |
149 | poorly-designed | 2 |
150 | pro-coagulatory | 4 |
151 | pseudosac | 2 |
152 | radial-to-fa | 1 |
153 | random-order | 22 |
154 | random-ordered | 1 |
155 | random-sequencing | 1 |
156 | randomized-group | 1 |
157 | randomized-order | 3 |
158 | randomized-sequence | 32 |
159 | randomized/controlled | 2 |
160 | raritan | 10 |
161 | rater-blinded | 38 |
162 | respirologist | 2 |
163 | response-conditional | 2 |
164 | rs17366568 | 4 |
165 | safflower-oil | 2 |
166 | self-delimiting | 2 |
167 | semi-randomized | 12 |
168 | sequence-crossover | 2 |
169 | sequence-randomized | 6 |
170 | seven-way | 2 |
171 | simple-blind | 8 |
172 | single-blind | 1,832 |
173 | single-blinded | 735 |
174 | single-dummy | 1 |
175 | single-masked | 80 |
176 | single-period | 6 |
177 | single-sequence | 7 |
178 | singleblind | 3 |
179 | six-centre | 2 |
180 | six-contact | 3 |
181 | six-period | 2 |
182 | six-site | 2 |
183 | split-body | 6 |
184 | split-face | 91 |
185 | split-wound | 2 |
186 | stepped-wedged | 2 |
187 | subject-blind | 7 |
188 | subject-blinded | 9 |
189 | subject-masked | 5 |
190 | tarrytown | 5 |
191 | three-by-two | 2 |
192 | three-level-three-factor | 1 |
193 | three-period | 109 |
194 | three-period- | 1 |
195 | three-sequence | 10 |
196 | three-station | 3 |
197 | three-treatment | 36 |
198 | titration-based | 3 |
199 | triglycerols | 2 |
200 | triple-blind | 78 |
201 | triple-blinded | 24 |
202 | triple-masked | 14 |
203 | triple-period | 1 |
204 | two-by-three | 1 |
205 | two-by-two | 57 |
206 | two-latin-square | 1 |
207 | two-panel | 4 |
208 | two-period | 249 |
209 | two-sequence | 64 |
210 | two-treatment | 86 |
211 | yellow-pigmented | 3 |
212 | ≤20-week | 1 |
1 | mpac* | 2 |
2 | 6.25- | 3 |
3 | demographic- | 3 |
4 | three-period- | 1 |
5 | b.c. | 3 |
6 | 2-by-2 | 33 |
7 | ga2 | 2 |
8 | '2x2 | 1 |
9 | 2x2x2 | 2 |
10 | 2×2 | 97 |
11 | 2×2×2 | 5 |
12 | 2×3 | 9 |
13 | 4×3 | 1 |
14 | 4x4 | 1 |
15 | 2×4 | 4 |
16 | rs17366568 | 4 |
17 | hdac9 | 4 |
18 | cyp2a | 3 |
19 | ct3a | 2 |
20 | anorexia/nausea | 5 |
21 | radial-to-fa | 1 |
22 | monrovia | 21 |
23 | pseudosac | 2 |
24 | beta-bhc | 4 |
25 | orbital-specific | 1 |
26 | aclc | 3 |
27 | 92-d | 1 |
28 | 23-bed | 3 |
29 | expectancy-enhanced | 2 |
30 | one-side-blinded | 1 |
31 | double-blinded | 2,117 |
32 | single-blinded | 735 |
33 | triple-blinded | 24 |
34 | dose-blinded | 2 |
35 | non-blinded | 193 |
36 | examiner-blinded | 19 |
37 | rater-blinded | 38 |
38 | subject-blinded | 9 |
39 | participant-blinded | 15 |
40 | patient-blinded | 41 |
41 | nonblinded | 135 |
42 | stepped-wedged | 2 |
43 | double-masked | 640 |
44 | single-masked | 80 |
45 | triple-masked | 14 |
46 | investigator-masked | 46 |
47 | evaluator-masked | 5 |
48 | subject-masked | 5 |
49 | nonmasked | 9 |
50 | allocation-concealed | 8 |
51 | historical-controlled | 3 |
52 | pbo-controlled | 4 |
53 | randomized/controlled | 2 |
54 | gas-cooled | 4 |
55 | guideline-informed | 5 |
56 | poorly-designed | 2 |
57 | parallel-grouped | 2 |
58 | random-ordered | 1 |
59 | nonsponsored | 3 |
60 | kindergarten-based | 7 |
61 | novobiocin-based | 2 |
62 | titration-based | 3 |
63 | holter-based | 1 |
64 | four-phased | 2 |
65 | pink-pigmented | 3 |
66 | yellow-pigmented | 3 |
67 | sequence-randomized | 6 |
68 | semi-randomized | 12 |
69 | 6-week-randomized | 1 |
70 | esl-bid | 3 |
71 | placebo-and | 3 |
72 | double-bind | 6 |
73 | doubled-blind | 8 |
74 | double-blind | 22,638 |
75 | single-blind | 1,832 |
76 | triple-blind | 78 |
77 | simple-blind | 8 |
78 | subject-blind | 7 |
79 | patient-blind | 7 |
80 | partially-blind | 3 |
81 | doubleblind | 22 |
82 | singleblind | 3 |
83 | split-wound | 2 |
84 | 2-period | 154 |
85 | 3-period | 67 |
86 | 4-period | 30 |
87 | 5-period | 11 |
88 | 6-period | 1 |
89 | three-period | 109 |
90 | single-period | 6 |
91 | triple-period | 1 |
92 | nine-period | 2 |
93 | five-period | 8 |
94 | two-period | 249 |
95 | four-period | 64 |
96 | 2-treatment-period | 1 |
97 | six-period | 2 |
98 | high-standard | 2 |
99 | split-face | 91 |
100 | 10-sequence | 1 |
101 | 2-sequence | 40 |
102 | 3-sequence | 5 |
103 | 5-sequence | 2 |
104 | 6-sequence | 5 |
105 | randomized-sequence | 32 |
106 | three-sequence | 10 |
107 | single-sequence | 7 |
108 | one-sequence | 3 |
109 | two-sequence | 64 |
110 | phytosterol-free | 1 |
111 | guilt-free | 1 |
112 | two-by-three | 1 |
113 | 5-stage | 2 |
114 | naugle | 1 |
115 | hirsutine | 8 |
116 | two-latin-square | 1 |
117 | six-centre | 2 |
118 | manual-electroacupuncture | 2 |
119 | six-site | 2 |
120 | gram-stain-negative | 7 |
121 | mazf | 3 |
122 | 0.10g | 2 |
123 | random-sequencing | 1 |
124 | dosage-ranging | 2 |
125 | flexible-dosing | 7 |
126 | fast-disintegrating | 4 |
127 | self-delimiting | 2 |
128 | four-branch | 1 |
129 | four-brush | 1 |
130 | ≤20-week | 1 |
131 | 40-wk | 2 |
132 | partial-factorial | 4 |
133 | europa-trial | 1 |
134 | response-conditional | 2 |
135 | two-panel | 4 |
136 | four-variable-three-level | 1 |
137 | safflower-oil | 2 |
138 | nonbiphenyl | 2 |
139 | niederman | 4 |
140 | raritan | 10 |
141 | oxyfluorfen | 6 |
142 | craftsmen | 2 |
143 | pectolinarigenin | 5 |
144 | linarin | 5 |
145 | myosuppressin | 4 |
146 | blinded-adjudication | 2 |
147 | three-station | 3 |
148 | 2-condition | 2 |
149 | 4-intervention | 1 |
150 | burlington | 12 |
151 | bloomington | 15 |
152 | easy-to-learn | 2 |
153 | tarrytown | 5 |
154 | double-placebo | 15 |
155 | three-by-two | 2 |
156 | two-by-two | 57 |
157 | 1-group | 3 |
158 | randomized-group | 1 |
159 | family-member | 2 |
160 | balanced-order | 4 |
161 | randomized-order | 3 |
162 | random-order | 22 |
163 | 2-center | 31 |
164 | 14-center | 3 |
165 | 5-center | 6 |
166 | bicenter | 3 |
167 | sequence-crossover | 2 |
168 | multi-crossover | 2 |
169 | three-level-three-factor | 1 |
170 | dedas | 3 |
171 | dimensionalities | 2 |
172 | coumarines | 2 |
173 | 16-months | 2 |
174 | necrobiosis | 4 |
175 | triglycerols | 2 |
176 | fully-within-groups | 1 |
177 | four-groups | 1 |
178 | chondroblasts | 2 |
179 | six-contact | 3 |
180 | periinfarct | 3 |
181 | 5-night | 1 |
182 | nonexplicit | 3 |
183 | nine-participant | 1 |
184 | histology-independent | 4 |
185 | 2-treatment | 26 |
186 | 3-treatment | 14 |
187 | 4-treatment | 7 |
188 | 5-treatment | 6 |
189 | three-treatment | 36 |
190 | two-treatment | 86 |
191 | four-treatment | 10 |
192 | 28-component | 2 |
193 | respirologist | 2 |
194 | corkscrew | 2 |
195 | 4-way | 38 |
196 | 5-way | 12 |
197 | 6-way | 4 |
198 | 7-way | 1 |
199 | five-way | 17 |
200 | seven-way | 2 |
201 | four-way | 46 |
202 | split-body | 6 |
203 | beefy | 2 |
204 | counter-intuitively | 2 |
205 | double-dummy | 460 |
206 | single-dummy | 1 |
207 | bi-lobectomy | 2 |
208 | duodenoileostomy | 2 |
209 | cary | 25 |
210 | pro-coagulatory | 4 |
211 | konstanz | 4 |
212 | 2² | 1 |